FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890797827> ?p ?o ?g. }

• W2890797827 endingPage "5216" @default.
• W2890797827 startingPage "5207" @default.
• W2890797827 abstract "A monoclonal antibody (mAb) against the blood-brain barrier (BBB) transferrin receptor (TfR) is a potential agent for delivery of biologic drugs to the brain across the BBB. However, to date, no TfRMAb has been tested with chronic dosing in a primate model. A humanized TfRMAb against the human (h) TfR1, which cross reacts with the primate TfR, was genetically engineered with high affinity (ED50 = 0.18 ± 0.04 nM) for the human TfR type 1 (TfR1). For acute dosing, the hTfRMAb was tritiated and injected intravenously (IV) in the Rhesus monkey, which confirmed rapid delivery of the humanized hTfRMAb into both brain parenchyma, via transport across the BBB, and into cerebrospinal fluid (CSF), via transport across the choroid plexus. For chronic dosing, a total of 8 adult Rhesus monkeys (4 males, 4 females) were treated twice weekly for 4 weeks with 0, 3, 10, or 30 mg/kg of the humanized hTfRMAb via a 60 min IV infusion for a total of 8 doses prior to euthanasia and microscopic examination of brain and peripheral organs. A pharmacokinetics analysis showed the plasma clearance of the hTfRMAb in the primate was nonlinear, and plasma clearance was increased over 20-fold with chronic treatment of the low dose, 3 mg/kg, of the antibody. Chronic treatment of the primates with the 30 mg/kg dose caused anemia associated with suppressed blood reticulocytes. Immunohistochemistry of terminal brain tissue showed microglia activation, based on enhanced IBA1 immuno-staining, in conjunction with astrogliosis, based on increased GFAP immuno-staining. Moderate axonal/myelin degeneration was observed in the sciatic nerve. Further studies need to be conducted to determine if this neuropathology is induced by the antibody effector function, or is an intrinsic property of targeting the TfR in brain. The results indicate that chronic treatment of Rhesus monkeys with a humanized hTfRMAb may have a narrow therapeutic index, with associated toxicity related to microglial activation and astrogliosis of the brain." @default.
• W2890797827 created "2018-09-27" @default.
• W2890797827 creator A5021677800 @default.
• W2890797827 creator A5027480548 @default.
• W2890797827 creator A5073892880 @default.
• W2890797827 creator A5078156349 @default.
• W2890797827 creator A5087873984 @default.
• W2890797827 date "2018-09-18" @default.
• W2890797827 modified "2023-10-01" @default.
• W2890797827 title "Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor" @default.
• W2890797827 cites W133175338 @default.
• W2890797827 cites W1516338367 @default.
• W2890797827 cites W1919971299 @default.
• W2890797827 cites W1927066019 @default.
• W2890797827 cites W1967541880 @default.
• W2890797827 cites W1971951579 @default.
• W2890797827 cites W1993152909 @default.
• W2890797827 cites W1995458780 @default.
• W2890797827 cites W2002851710 @default.
• W2890797827 cites W2014930853 @default.
• W2890797827 cites W2021565098 @default.
• W2890797827 cites W2025919785 @default.
• W2890797827 cites W2026422955 @default.
• W2890797827 cites W2027170943 @default.
• W2890797827 cites W2029440546 @default.
• W2890797827 cites W2056672961 @default.
• W2890797827 cites W2056925317 @default.
• W2890797827 cites W2076807570 @default.
• W2890797827 cites W2077099362 @default.
• W2890797827 cites W2078004577 @default.
• W2890797827 cites W2087597093 @default.
• W2890797827 cites W2088789369 @default.
• W2890797827 cites W2102754060 @default.
• W2890797827 cites W2105197440 @default.
• W2890797827 cites W2137541358 @default.
• W2890797827 cites W2138037217 @default.
• W2890797827 cites W2162676548 @default.
• W2890797827 cites W2164775227 @default.
• W2890797827 cites W2171636653 @default.
• W2890797827 cites W2314371091 @default.
• W2890797827 cites W2510592490 @default.
• W2890797827 cites W2578585563 @default.
• W2890797827 cites W2753001377 @default.
• W2890797827 cites W2782455960 @default.
• W2890797827 cites W2830135676 @default.
• W2890797827 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00730" @default.
• W2890797827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30226787" @default.
• W2890797827 hasPublicationYear "2018" @default.
• W2890797827 type Work @default.
• W2890797827 sameAs 2890797827 @default.
• W2890797827 citedByCount "44" @default.
• W2890797827 countsByYear W28907978272019 @default.
• W2890797827 countsByYear W28907978272020 @default.
• W2890797827 countsByYear W28907978272021 @default.
• W2890797827 countsByYear W28907978272022 @default.
• W2890797827 countsByYear W28907978272023 @default.
• W2890797827 crossrefType "journal-article" @default.
• W2890797827 hasAuthorship W2890797827A5021677800 @default.
• W2890797827 hasAuthorship W2890797827A5027480548 @default.
• W2890797827 hasAuthorship W2890797827A5073892880 @default.
• W2890797827 hasAuthorship W2890797827A5078156349 @default.
• W2890797827 hasAuthorship W2890797827A5087873984 @default.
• W2890797827 hasConcept C112705442 @default.
• W2890797827 hasConcept C126322002 @default.
• W2890797827 hasConcept C142724271 @default.
• W2890797827 hasConcept C159654299 @default.
• W2890797827 hasConcept C203014093 @default.
• W2890797827 hasConcept C22814914 @default.
• W2890797827 hasConcept C2776538271 @default.
• W2890797827 hasConcept C2778402981 @default.
• W2890797827 hasConcept C32264632 @default.
• W2890797827 hasConcept C529278444 @default.
• W2890797827 hasConcept C542903549 @default.
• W2890797827 hasConcept C71924100 @default.
• W2890797827 hasConcept C98274493 @default.
• W2890797827 hasConceptScore W2890797827C112705442 @default.
• W2890797827 hasConceptScore W2890797827C126322002 @default.
• W2890797827 hasConceptScore W2890797827C142724271 @default.
• W2890797827 hasConceptScore W2890797827C159654299 @default.
• W2890797827 hasConceptScore W2890797827C203014093 @default.
• W2890797827 hasConceptScore W2890797827C22814914 @default.
• W2890797827 hasConceptScore W2890797827C2776538271 @default.
• W2890797827 hasConceptScore W2890797827C2778402981 @default.
• W2890797827 hasConceptScore W2890797827C32264632 @default.
• W2890797827 hasConceptScore W2890797827C529278444 @default.
• W2890797827 hasConceptScore W2890797827C542903549 @default.
• W2890797827 hasConceptScore W2890797827C71924100 @default.
• W2890797827 hasConceptScore W2890797827C98274493 @default.
• W2890797827 hasIssue "11" @default.
• W2890797827 hasLocation W28907978271 @default.
• W2890797827 hasLocation W28907978272 @default.
• W2890797827 hasOpenAccess W2890797827 @default.
• W2890797827 hasPrimaryLocation W28907978271 @default.
• W2890797827 hasRelatedWork W1542251585 @default.
• W2890797827 hasRelatedWork W1555875393 @default.
• W2890797827 hasRelatedWork W1998531393 @default.
• W2890797827 hasRelatedWork W2007018977 @default.
• W2890797827 hasRelatedWork W2021711410 @default.

• next